MediciNova, Inc. 2019 Form 10-K Summary
Business Context and Reporting Period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. Its primary programs are MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases. The pipeline also includes MN-221 (bedoradrine) for acute asthma exacerbations and MN-029 (denibulin) for solid tumors.
This is an annual report for the fiscal year ended December 31, 2019, filed February 13, 2020. The filing does not present a separate fourth-quarter financial statement. The company had no products approved for commercial sale and no product-sales revenue.
Financial Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research, development and patent expense | $6.1 million | $5.6 million | Increased $0.5 million |
| General and administrative expense | $8.0 million | $10.0 million | Decreased $2.0 million |
| Total operating expenses | $14.0 million | $15.6 million | Decreased $1.6 million |
| Operating loss | $14.0 million | $15.6 million | Improved $1.6 million |
| Net loss | $12.9 million | $14.7 million | Improved $1.7 million |
| Basic and diluted loss per share | $0.30 | $0.36 | Improved |
| Net cash used in operating activities | $9.1 million | $9.1 million | Essentially unchanged |
| Cash and cash equivalents | $63.8 million | $62.3 million | Increased $1.5 million |
Because revenue was zero, gross and operating margins are not meaningful. Interest income was $1.1 million, compared with $0.9 million in 2018, partially offsetting operating losses. Other expense was approximately $46,000. The company reported no conventional long-term debt; total liabilities were $4.3 million, including $1.7 million of deferred revenue, $0.2 million of deferred tax liabilities, and approximately $0.4 million of operating lease liabilities.
Working capital was $62.1 million and total assets were $79.2 million at December 31, 2019. Stockholders’ equity was $74.9 million. The accumulated deficit was $369.1 million. The company had 43.9 million shares outstanding at year-end and 43.96 million shares outstanding as of February 12, 2020.
Material Changes Versus the Prior Comparable Period
- Net loss narrowed by approximately $1.7 million, primarily because general and administrative expense declined by $2.0 million.
- Research and development expense increased by $0.5 million, primarily from greater clinical-trial activity for MN-166, partly offset by lower performance-based stock compensation.
- Stock-based compensation declined to $4.1 million from $6.3 million.
- Operating cash use remained approximately $9.1 million despite the lower net loss.
- The company raised approximately $6.5 million of net proceeds from sales of 804,963 shares under its ATM program, compared with $1.5 million from 200,000 shares in 2018.
- The 2015 ATM agreement was terminated and replaced on August 23, 2019 with a new ATM agreement permitting sales of up to $75.0 million of common stock. The remaining availability under that agreement is not clearly stated in the filing text.
- The company adopted the new lease accounting standard in 2019, recognizing approximately $0.4 million of right-of-use assets and approximately $0.4 million of lease liabilities.
Pipeline, Outlook, Risks and Unusual Items
- MN-166 had completed Phase 2b development in progressive MS and was advancing into an ongoing Phase 2b/3 ALS trial. FDA Fast Track designations applied to progressive MS, ALS and methamphetamine dependence; orphan-drug designations applied to ALS and glioblastoma.
- MN-001 remained in development for IPF, with an ongoing Phase 2 trial. Its NASH trial was terminated early after an interim analysis showed reduced serum triglycerides, but no NASH revenue or approval had resulted.
- MN-221 development was effectively partner-dependent after the FDA identified risk-benefit and hospitalization outcomes as key issues for further development.
- Management expected research and development expenses to increase in 2020 and expected continued operating losses for the foreseeable future.
- Management stated that available working capital was sufficient to fund operations at least through the end of 2021, but also noted that additional capital or strategic alliances may be required depending on clinical-development decisions and spending.
- Potential future milestone payments were $10.0 million for MN-166 and MN-001 and $33.5 million for the other licensed products. The timing and occurrence of these payments were uncertain, and no minimum royalties were required.
- The company relies on third parties for clinical trials, manufacturing and potential commercialization, and has no internal sales or marketing capabilities.
- Key risks include clinical-trial failure or delay, regulatory non-approval, inability to raise capital, dilution from future equity sales, reliance on licensed intellectual property, limited compound-of-matter protection for several programs, manufacturing dependence, competition and inability to establish commercial partnerships.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and no subsequent events requiring recognition or disclosure. BDO USA, LLP issued unqualified opinions on the financial statements and internal control over financial reporting.
Important Facts for Investors to Verify
- Confirm current cash runway against the pace of operating cash use and planned ALS, IPF and other clinical-trial expenditures.
- Track additional issuances under the $75.0 million ATM facility and the resulting dilution to existing shareholders.
- Verify enrollment, timing, design and regulatory status of the MN-166 ALS Phase 2b/3 trial.
- Assess whether the positive Phase 2 findings for progressive MS and the interim NASH triglyceride results translate into successful pivotal trials and regulatory approvals.
- Review the status of the ongoing MN-001 IPF trial and any future NASH development strategy.
- Evaluate the expiration and enforceability of method-of-use patents, particularly because composition-of-matter protection has expired for MN-166, MN-001 and MN-221.
- Monitor potential license milestones, partnership activity and the company’s ability to fund operations without substantial equity dilution.